Last reviewed · How we verify
NCT05626634
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Phase 2 trial testing LP352, bexicaserin in Developmental and Epileptic Encephalopathy in 41 participants. Completed in 20 December 2024.
20 December 2024
Quick facts
| Lead sponsor | Longboard Pharmaceuticals |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 41 |
| Start date | 8 November 2022 |
| Primary completion | 20 December 2024 |
| Estimated completion | 20 December 2024 |
| Sites | 28 locations across United States, Australia |
Drugs / interventions tested
- LP352, bexicaserin — full drug profile →
Conditions studied
- Developmental and Epileptic Encephalopathy — all drugs for Developmental and Epileptic Encephalopathy →
- Dravet Syndrome — all drugs for Dravet Syndrome →
- Lennox-Gastaut Syndrome — all drugs for Lennox-Gastaut Syndrome →
Sponsor
Longboard Pharmaceuticals — full company profile →
Who can join
Adults 12 to 65, any sex, with Developmental and Epileptic Encephalopathy or Dravet Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical trials for Lennox-Gastaut syndrome: Challenges and priorities.
Knowles JK, Warren AEL, Mohamed IS, Stafstrom CE, et al · · 2024 · cited 17× · PMID 39440617 · DOI 10.1002/acn3.52211 -
Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.
Balestrini S, Scheffer IE. · · 2026 · PMID 41712149 · DOI 10.1007/s40263-026-01276-x
Verify or expand the search:
- PubMed search for NCT05626634
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Developmental and Epileptic Encephalopathy
Currently open trials in the same condition.
- NCT06719141 — A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) · Phase 3 · recruiting
- NCT06380192 — Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data · recruiting
- NCT04937062 — Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy · EARLY_PHASE1 · active not recruiting
Other Longboard Pharmaceuticals trials
Trials by the same sponsor.
- NCT06908226 — A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) · Phase 3 · enrolling by invitation
- NCT06719141 — A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) · Phase 3 · recruiting
- NCT06660394 — A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) · Phase 3 · recruiting
- NCT05364021 — Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies · Phase 1, PHASE2 · completed
- NCT06149663 — Intermediate-Size Expanded Access Protocol (EAP) for LP352 · available
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05626634 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Longboard Pharmaceuticals
- Last refreshed: 3 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05626634.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing